MANNITOL 10% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mannitol 10%, and when can generic versions of Mannitol 10% launch?
Mannitol 10% is a drug marketed by B Braun, Hospira, Miles, and Icu Medical Inc. and is included in five NDAs.
The generic ingredient in MANNITOL 10% is mannitol. There are eighteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the mannitol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MANNITOL 10%?
- What are the global sales for MANNITOL 10%?
- What is Average Wholesale Price for MANNITOL 10%?
Summary for MANNITOL 10%
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 225 |
| DailyMed Link: | MANNITOL 10% at DailyMed |
Recent Clinical Trials for MANNITOL 10%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University Hospital, Geneva | Phase 3 |
| Morten Hostrup, PhD | N/A |
| University Hospital Inselspital, Berne | Early Phase 1 |
Pharmacology for MANNITOL 10%
| Drug Class | Osmotic Diuretic |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for MANNITOL 10%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun | MANNITOL 10% | mannitol | INJECTABLE;INJECTION | 016080-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| B Braun | MANNITOL 10% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 020006-002 | Jul 26, 1993 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | MANNITOL 10% | mannitol | INJECTABLE;INJECTION | 016269-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MANNITOL 10%
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
